PGHL FY26 Sales Up 16% to ₹1385 Cr, PAT Up 30%; Recommends ₹45 Final Dividend
Procter & Gamble Health Limited reported FY26 sales of ₹1385 crore (up 16%) and PAT of ₹327 crore (up 30%) compared to the prior comparable 12-month period. Q4 FY26 saw sales up 20% to ₹365 crore and PAT up 55% to ₹95 crore. The Board recommended a final dividend of ₹45 per share, bringing the total to ₹205 per share for the fiscal.
The announcement includes robust financial performance metrics, a significant increase in dividend payout, and highlights strategic investments in product innovation and market capabilities, all of which are material for investors.
The company reported strong year-on-year growth in both sales and profit for the quarter and the full fiscal year, along with a significant dividend payout recommendation.
Procter & Gamble Health Limited (PGHL) announced its audited financial results for the financial year ended March 31, 2026. The company reported a 20% increase in sales to ₹365 crore and a 55% rise in Profit After Tax (PAT) to ₹95 crore for the fourth quarter ended March 31, 2026, compared to the previous year.
For the full fiscal year ended March 31, 2026, PGHL recorded sales of ₹1385 crore, a 16% increase, and PAT of ₹327 crore, a 30% increase, compared to the comparable 12-month period in the last year (April 2024 - March 2025). The company noted a change in its financial year reporting from July 1-June 30 to April 1-March 31, making the current fiscal year's performance indexed against a 12-month period.
Milind Thatte, Managing Director, stated that the company delivered strong, consistent growth by investing in innovations like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, along with strengthening supply chain and go-to-market capabilities. The company also highlighted its CSR initiative, P&G Sehat, which has impacted over 15 lakh lives.
The Board of Directors has recommended a final dividend of ₹45 per equity share for the financial year ended March 31, 2026. Combined with the interim dividend of ₹160 per share paid earlier, the total dividend payout for the fiscal year amounts to ₹205 per share, subject to shareholder approval at the ensuing 59th Annual General Meeting.
What to do with a filing like this
Procter & Gamble Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Health Limited. Read the original for the full detail.